Hims & Hers Health Surges 2.85% on Q3 Earnings and GLP-1 Expansion – What’s Next?

Summary
• Hims & Hers Health (HIMS) surges 2.85% to $44.01, trading above its 52-week low of $19.15
• Q3 2025 revenue jumps 49% to $599M, subscribers hit 2.47M, and Adjusted EBITDA grows 53%
• Company announces GLP-1 microdosing expansion and active discussions with Novo Nordisk
• Intraday range of $43.70–$46.82 highlights volatility amid bullish technical indicators

Today’s sharp rally in HIMS reflects a confluence of strong earnings, strategic expansion into GLP-1 therapies, and speculative momentum. With the stock trading near its 52-week low, the move underscores investor optimism about the company’s ability to scale personalized care solutions and capitalize on the booming weight management market.

Q3 Earnings and GLP-1 Expansion Drive HIMS Rally
Hims & Hers Health’s 2.85% intraday gain is fueled by its Q3 2025 results, which showed 49% revenue growth to $599 million and a 21% increase in subscribers to 2.47 million. The company’s expansion into compounded GLP-1 microdosing treatment plans, announced last week, has positioned it as a key player in the high-demand weight loss drug sector. Additionally, ongoing discussions with Novo Nordisk to offer Wegovy injections and oral treatments (pending FDA approval) have heightened speculative interest. These developments, combined with a narrowing of 2025 revenue guidance to $2.335–$2.355 billion, signal confidence in the company’s ability to monetize its platform and scale operations.

Options and Technicals: Navigating HIMS’ Volatility and Momentum
• RSI: 15.05 (oversold)
• MACD: -2.66 (bearish), Signal Line: -1.72, Histogram: -0.94
• Bollinger Bands: Upper $61.98, Middle $50.75, Lower $39.52 (current price near lower band)
• 200D MA: $46.56 (below current price)
• Support/Resistance: 30D $57.97–$58.37, 200D $47.91–$48.78

HIMS is trading in a short-term bearish trend but within a long-term ranging pattern. The RSI at 15.05 suggests oversold conditions, while the MACD histogram indicates weakening bearish momentum. The stock is near its 200-day moving average ($46.56) and lower Bollinger Band ($39.52), hinting at potential short-term rebound. For options, focus on high-liquidity contracts with moderate deltas and strong gamma/theta profiles:

Top Option 1: HIMS20251114C45
• Type: Call
• Strike: $45
• Expiration: 2025-11-14
• IV: 89.61% (high volatility)
• Leverage Ratio: 20.61%
• Delta: 0.465 (moderate sensitivity)
• Theta: -0.204 (rapid time decay)
• Gamma: 0.061 (high sensitivity to price changes)
• Turnover: 433,916
• Payoff (5% upside): $0.22 per share (max(0, $46.21 - $45))
This call option offers a balance of leverage and liquidity, ideal for a short-term bullish bet if HIMS breaks above $45. The high gamma ensures responsiveness to price swings, while the moderate delta limits directional risk.

Top Option 2: HIMS20251114P45
• Type: Put
• Strike: $45
• Expiration: 2025-11-14
• IV: 84.08% (moderate volatility)
• Leverage Ratio: 14.49%
• Delta: -0.541 (moderate bearish exposure)
• Theta: -0.012 (slow time decay)
• Gamma: 0.065 (high sensitivity to price changes)
• Turnover: 132,088
• Payoff (5% downside): $0.22 per share (max(0, $45 - $41.81))
This put option provides downside protection if HIMS retests the $43.70 intraday low. The high gamma and moderate delta make it suitable for a volatile environment, while the low theta ensures minimal time decay.

Action Insight: Aggressive bulls may consider HIMS20251114C45 into a breakout above $45, while cautious bears might short HIMS20251114P45 if the stock fails to hold $43.70.

Backtest Hims & Hers Health Stock Performance
Below is the back-test report for a “3 % Intraday Surge” strategy on Hims & Hers Health (ticker: HIMS) covering 3 Jan 2022 – 5 Nov 2025. Key logic • Open a long position at the close of any session when HIMS’s closing price is ≥ 3 % above the prior-day close. • Risk-management overlay (auto-filled with standard defaults to avoid indefinite holding): – 8 % stop-loss – 12 % take-profit – Maximum holding period = 30 trading days (whichever exit trigger comes first) Results snapshot • Total return (notional 1-share trades, reinvested): ≈ 218 % • Annualised return: ≈ 41 % • Maximum drawdown: ≈ 47 % • Sharpe ratio: 0.88 • Average trade return: 4.8 % • Average gain / loss: +17.6 % / -13.4 % • Best / worst single-trade return: +41.4 % / -25.8 %A full interactive breakdown is available in the module below (trade log, equity curve, distribution of returns, etc.).Notes 1. Default risk-control levels (TP 12 %, SL 8 %, 30-day max hold) were applied because the original instruction did not specify exits; these are common swing-trade benchmarks. 2. Performance figures are gross of commissions/slippage; actual tradability may vary. 3. Consider experimenting with different profit-target / stop-loss levels or adding a volatility filter to refine risk-adjusted returns.Feel free to explore the interactive module above; let me know if you’d like further tweaks or deeper diagnostics.

HIMS at a Crossroads: Short-Term Bounce or Long-Term Consolidation?
HIMS’ 2.85% rally is a mix of earnings optimism and GLP-1-driven speculation, but technicals suggest a short-term bounce rather than a sustained breakout. The RSI at 15.05 and proximity to the lower Bollinger Band indicate oversold conditions, but the MACD’s bearish divergence warns of potential pullbacks. Investors should monitor the $45 level as a key inflection point: a close above could trigger a retest of the 200-day MA at $46.56, while a breakdown below $43.70 may reignite bearish momentum. Meanwhile, sector leader UnitedHealth Group (UNH) is down 1.16%, highlighting mixed sentiment in healthcare. For HIMS, the path forward hinges on execution of its GLP-1 strategy and Novo Nordisk partnership updates. Watch for $45 breakout or $43.70 breakdown to define next steps.